Skip to content

PiXL for Correction of Hyperopia

Photorefractive Intrastromal Corneal Crosslinking (PiXL) for Correction of Hyperopia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03805425
Enrollment
25
Registered
2019-01-15
Start date
2016-12-31
Completion date
2021-03-31
Last updated
2021-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperopia

Keywords

Hypeorpia, Crosslinking, PiXL

Brief summary

This clinical study aims to investigate the efficacy and safety of PiXL in the refractive correction of low hyperopia.

Detailed description

This clinical study aims to investigate the efficacy and safety of PiXL in the refractive correction of low hyperopia.Slightly modified settings from previously published study is applied to eyes with low hyperopia with an expected refractive change of 0.75 D. Aim is to evaluate the refractive outcome of this procedure.

Interventions

RADIATIONPiXL

The system is set to deliver 30 mW/cm2 UVA irradiance in pulsed intervals of 1 second on and 1 second off to 5 to 9 mm diameter corneal annulus. Total energy delivered is 15J.

Sponsors

Gemini Eye Clinic
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* low hyperopia of spherical equivalent from +0.5 up to +1.75 D sp. eq. * astigmatism up to 0.75 Dcyl * corneal thickness above 400 µm * endothelial cell density above 1500 cell/mm2

Exclusion criteria

* any prior corneal surgery or any eye surgery within the last 3 months, * any corneal pathology e.g. corneal scar or dystrophy * unstable refraction * patient not able to understand and sign informed consent * patients with connective tissue disorder or uncontrolled diabetes * pregnant or lactating women * aphakic eyes or pseudophakic eyes without UV blocking IOL

Design outcomes

Primary

MeasureTime frameDescription
Change in Uncorrected Distance Visual AcuityMonth 12Best distance visual acuity tested without any correction
Change in Subjective RefractionMonth 12Spherical and cylindrical correction

Secondary

MeasureTime frameDescription
Change in Higher Order AberrationsMonth 12Higher Order Aberrations assessed using Pentacam
Change in pachymetryMonth 12Change in mean cornea thickness in 8.0 mm ring provided by Pentacam
Change in Spherical aberrationMonth 12Spherical aberration assessed using Pentacam
Change in Corrected Distance Visual AcuityMonth 12Best distance visual acuity tested with the best correction
Subjective questionnaire scoreMonth 12Questionnaire assessing participants discomfort at 6 months in respect to their photophobia, pain and dry eye.
Change in keratometryMonth 12Change in keratomery parameter K2-K1provided by Pentacam

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026